Fundamental Analysis of Sun Pharmaceutical Industries Ltd. - Growth / Value Index
SUNPHARMA - Valuation Highlights
Valuation Analysis
Tremendous increasing in Book Value last 3 year
Tsr Value Index - Poor Score of 23.61
Price to Book Ratio of 5.71 suggesting that it is very expensive
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
---|---|---|---|---|---|
Price to Earning | 38.59 | 38.04 | -6.34 % | ||
Price to Book | 5.71 | 5.78 | -5.46 % | 2.74 | |
Price to Sales | 7.45 | 7.93 | -1.08 % | ||
Enterprise Value to EBITDA Multiple | 24.69 | -10.12 % |
SUNPHARMA - Profitability Highlights
Profitability Analysis
Piotroski F Score - Excellent Value of 8.0
Tremendous increasing trend in Net Profit for last 3 year
Company Earning excess return
All key Trailing Twelve Months Margin growing by 15 %
EBITDA is continuously increasing for last 3 Years
Steady ROE in range of 15 to 20 for last 3 years
Steady ROA in range of 8 to 12 for last 3 years
Good Return On Capital Employed of 14.82
Good Return on Equity of 14.98% is achieved by the company
Good Net Margin of 19.29% is achieved by the company
Very Low Dividend Yield of 0 %
Low Earning Yield of 2.59 %
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
---|---|---|---|---|---|
Return On Equity | 14.98 | 15.18 | 0.940 % | 3.14 | |
Return On Asset | 11.64 | 11.91 | 6.25 % | 2.47 | |
Net Profit Margin | 19.29 | 20.85 | 5.61 % | 16.45 | |
Operating Profit Margin | 64.93 | 23.71 | 12.41 % | 29.40 | |
EBITDA Margin | 30.37 | 31.49 | 10.02 % | 28.33 |
Highlights
Market Cap | 4009.05 B |
Enterprise Value | 3926.43 B |
Price/Book TTM | 5.71 |
Outstanding Share | 2399.33 M |
Float/ Outstanding Share | 44.39% |
Dividend Yield | 0 % |
Share Holding
Guru Numbers
Price/Graham No | 3.09 |
Peter Lynch Ratio | 0.370 |
Piotroski F Score | 8.00 |
Altman Z Score | 14.56 |
Sloan Ratio | 0.0239 |
Peter Lynch Fair Value | 761.63 |
SUNPHARMA - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Quarterly sales in last 5 years is trending up
Steady increase in Total Assets for last 3 Years
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | 53777.09 (Cr) | 8.42 % | 6.89 % |
Gross Profit | 39339.68 (Cr) | 59.75 % | 7.79 % |
EBITDA | 16331.46 (Cr) | 19.27 % | 0.920 % |
Net Profit | 10376.10 (Cr) | 14.50 % | 5.79 % |
EPS | 43.30 | 14.29 % | NA |
SUNPHARMA - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 93.75
Altman Z Score of 14.56 suggests good Stability
Decreasing debt with Increasing revenue
Company financial liquidity has improved
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ | Screener/ About |
---|---|---|---|---|
Debt to Equity Ratio | 0.0278 | -40.47 % | 0.0277 | |
Cash Ratio | 0.623 | -44.63 % | ||
Quick Ratio | 2.33 | 17.72 % | 2.33 | |
Shareholders Equity | 78.41 | 5.26 % | ||
Debt to EBITDA | 0.121 | -43.39 % |
Historical Valuation Ratios of Sun Pharmaceutical Industries Ltd.
Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Sun Pharmaceutical Industries Ltd.
Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Sun Pharmaceutical Industries Ltd.
Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Sun Pharmaceutical Industries Ltd.
Historical Solvency Ratios
Loading ...
